CORRECTED-BRIEF-AbbVie Inc outlook FY adjusted EPS USD 13.87 - 14.07

Bitget

News

Reuters2026/07/31 11:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jul 31 (Reuters) - AbbVie Inc Q2 Global Skyrizi revenue USD 5,505 million.

Q2 Global Rinvoq revenue USD 2,525 million
Q2 EPS USD 2.03
Q2 revenue USD 16,990 million vs. IBES estimate USD 16,765 million
Q2 Global Humira revenue USD 756 million
Q2 Adjusted EPS USD 3.65 Vs. IBES Estimate USD 3.6
Q2 RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.17/SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE
FY 2026 ADJ EPS GUIDANCE INCLUDES $0.14 /SHARE DILUTIVE IMPACT RELATED TO ACQUISITION OF APOGEE THERAPEUTICS

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CORRECTED-BRIEF-AbbVie Inc outlook FY adjusted EPS USD 13.87 - 14.07

You may also like

Crypto prices